Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market by Drug (Hyper-CVAD Regimen, Linker Regimen, Nucleoside Metabolic Inhibitors, Targeted Drugs & Immunotherapy, CALGB 8811 Regimen, and Oncaspar), and Type (Pediatric and Adult): Global Oppo

Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market by Drug (Hyper-CVAD Regimen, Linker Regimen, Nucleoside Metabolic Inhibitors, Targeted Drugs & Immunotherapy, CALGB 8811 Regimen, and Oncaspar), and Type (Pediatric and Adult): Global Opportunity Analysis and Industry Forecast, 2019–2026

The global acute lymphocytic/lymphoblastic leukemia therapeutics market accounted for $2,334.5 million in 2018, and is expected to reach $3,528.8 million by 2026, registering a CAGR of 5.3% from 2019 to 2026.

There has been a steady rise in the incidences of acute lymphoblastic leukemia (ALL) and the number of bone marrow biopsies across the world. Moreover, focus on R&D of leukemia therapeutics has been increased. These factors drive the growth of the acute lymphocytic/lymphoblastic leukemia therapeutics market. However, stringent regulatory paths for approvals of the therapeutics as well as the adverse side effects associated with these drugs restrict the growth of the global market. Nevertheless, the rise in number of clinical trials and new product approvals are anticipated to create newer opportunities in the emerging as well as the developed markets.

The acute lymphocytic/lymphoblastic leukemia therapeutics market has gained prominence in the recent years due to high prevalence of ALL worldwide and as a result, there is an increase in the need for leukemia diagnosis. Furthermore, growth potential offered by developing economies, increase in investment in the R&D of different leukemia, and rise in awareness of targeted therapies amongst the population present lucrative opportunities during the forecast period. However, patent expiry of the blockbuster drugs used in the treatment and higher costs involved in the therapies are expected to restrain the market growth.

The acute lymphocytic/lymphoblastic leukemia therapeutics market is segmented based on drugs, type, and region to provide a detailed assessment of the market. Based on drug, the market is divided into Hyper-CVAD Regimen, Linker Regimen, Nucleoside Metabolic Inhibitors (Clolar and Nelarabine), Targeted Drugs & Immunotherapy, CALGB 8811 Regimen, and Oncaspar. Based on type, the market is classified into pediatrics and adults. Based on region, the acute lymphocytic/lymphoblastic leukemia therapeutics market size is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY MARKET BENEFITS

The study provides an in-depth analysis of the global acute lymphocytic/lymphoblastic leukemia therapeutics market along with the current trends and future estimations to elucidate the imminent investment pockets.
The report presents a quantitative analysis of the market from 2018 to 2026 to enable stakeholders to capitalize on the prevailing market opportunities.
An extensive analysis of the market based on application assists in understanding the trends in the industry.
The key market players along with their strategies are thoroughly analyzed to understand the competitive outlook of the industry.

KEY MARKET SEGMENTS

By Type

Pediatrics
Adults

By Drug

Hyper-CVAD Regimen
Linker Regimen
Nucleoside Metabolic Inhibitors (Clolar and Nelarabine)
Targeted Drugs & Immunotherapy
CALGB 8811 Regimen
Oncaspar

By Region
North America
Europe
Asia-Pacific
LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT

Amgen, Inc.
Bristol-Myers Squibb Company
Erytech Pharma
Leadiant Biosciences, Inc. (Sigma-Tau Pharmaceuticals Inc.)
Novartis AG, Pfizer, Inc.
Rare Disease Therapeutics, Inc.
Sanofi
Spectrum Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited


CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits to Stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Porters five forces analysis
3.3.1. Bargaining power of suppliers
3.3.2. Threat of new entrants
3.3.3. Threat of substitutes
3.3.4. Competitive rivalry
3.3.5. Bargaining power among buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in the Incidences of Acute Lymphoblastic Leukemia
3.4.1.2. Rise in Number of New Product Approvals
3.4.2. Restraints
3.4.2.1. Patent Expiry of Blockbuster Drugs
3.4.2.2. Side effects of the treatment
3.4.3. Opportunity
3.4.3.1. Increase in number of Clinical Trials
CHAPTER 4: ACUTE LYMPHOCYTIC LEUKEMIA MARKET, BY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Pediatric
4.2.1. Market size and forecast
4.3. Adult
4.3.1. Market size and forecast
CHAPTER 5: ACUTE LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET, BY DRUG
5.1. Overvie
5.1.1. Market size and forecast
5.2. Hyper-CVAD regimen
5.2.1. Market size and forecast
5.3. Linker regimen
5.3.1. Market size and forecast
5.4. Nucleoside metabolic inhibitors (Clolar and Nelarabine)
5.4.1. Market size and forecast
5.5. Targeted drugs & immunotherapy
5.5.1. Market size and forecast
5.6. CALGB 8811 regimen
5.6.1. Market size and forecast
5.7. Oncaspar
5.7.1. Market size and forecast
CHAPTER 6: ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA THERAPEUTICS MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends and opportunities
6.3. Europe
6.3.1. Key market trends and opportunities
6.4. Asia-Pacific
6.4.1. Key market trends and opportunities
6.5. LAMEA
6.5.1. Key market trends and opportunities
CHAPTER 7: COMPANY PROFILES
7.1. AMGEN, INC
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments
7.2. BRISTOL-MYERS SQUIBB COMPANY
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.2.6. Key strategic moves and developments
7.3. ERYTECH PHARMA
7.3.1. Company overview
7.3.2. Operating business segments
7.3.3. Product portfolio
7.3.4. Key strategic moves and developments
7.4. LEADIANT BIOSCIENCES, INC. (SIGMA-TAU PHARMACEUTICALS INC.)
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.5. NOVARTIS AG
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.5.6. Key strategic moves and developments
7.6. PFIZER, INC
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments
7.7. RARE DISEASE THERAPEUTICS, INC.
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.8. SANOFI
7.8.1. Company overview
7.8.2. Operating business segments
7.8.3. Product portfolio
7.8.4. Business performance
7.9. SPECTRUM PHARMACEUTICALS, INC
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.9.6. Key strategic moves and developments
7.10. TAKEDA PHARMACEUTICAL COMPANY LIMITED
7.10.1. Company overview
7.10.2. Operating business segments
7.10.3. Product portfolio
7.10.4. Key strategic moves and developments
LIST OF TABLES
TABLE 01. ACUTE LYMPHOCYTIC LEUKEMIA MARKET, BY TYPE, 2018–2026 ($MILLION)
TABLE 02. ACUTE LYMPHOCYTIC LEUKEMIA MARKET FOR PEDIATRIC, BY REGION, 2018–2026 ($MILLION)
TABLE 03. ACUTE LYMPHOCYTIC LEUKEMIA MARKET FOR ADULTS, BY REGION, 2018–2026 ($MILLION)
TABLE 04. ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA THERAPEUTICS MARKET, BY DRUGS, 2018–2026 ($MILLION)
TABLE 05. ACUTE LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET FOR HYPER-CVAD, BY REGION, 2018–2026 ($MILLION)
TABLE 06. ACUTE LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET FOR LINKER REGIMEN, BY REGION, 2018–2026 ($MILLION)
TABLE 07. ACUTE LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET FOR NUCLEOSIDE METABOLIC INHIBITORS, BY REGION, 2018–2026 ($MILLION)
TABLE 08. ACUTE LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET FOR LINKER REGIMEN, BY REGION, 2018–2026 ($MILLION)
TABLE 09. ACUTE LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET FOR CALGB 8811 REGIMEN, BY REGION, 2018–2026 ($MILLION)
TABLE 10. ACUTE LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET FOR LINKER REGIMEN, BY REGION, 2018–2026 ($MILLION)
TABLE 11. ACUTE LYMPHOCYTIC LEUKEMIA THERAPEUTICS PRODUCT PIPELINE
TABLE 12. GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA THERAPEUTICS MARKET ($MILLION)
TABLE 13. NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA THERAPEUTICS MARKET, BY TYPE, VALUE (USD MILLION)
TABLE 14. NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA THERAPEUTICS MARKET, BY DRUGS, VALUE (USD MILLION)
TABLE 15. EUROPE ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA THERAPEUTICS MARKET, BY TYPE, VALUE (USD MILLION)
TABLE 16. EUROPE ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA THERAPEUTICS MARKET, BY DRUGS, VALUE (USD MILLION)
TABLE 17. ASIA-PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA THERAPEUTICS MARKET, BY TYPE, VALUE (USD MILLION)
TABLE 18. ASIA-PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA THERAPEUTICS MARKET, BY DRUGS, VALUE (USD MILLION)
TABLE 19. LAMEA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA THERAPEUTICS MARKET, BY TYPE, VALUE (USD MILLION)
TABLE 20. LAMEA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA THERAPEUTICS MARKET, BY DRUGS, VALUE (USD MILLION)
TABLE 21. AMGEN INC.: COMPANY SNAPSHOT
TABLE 22. AMGEN INC.: OPERATING SEGMENT
TABLE 23. AMGEN INC.: PRODUCT PORTFOLIO
TABLE 24. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
TABLE 25. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT SEGMENTS
TABLE 26. BECTON DICKINSON COMPANY: PRODUCT PORTFOLIO
TABLE 27. ERYTECH PHARMA: COMPANY SNAPSHOT
TABLE 28. ERYTECH PHARMA: OPERATING SEGMENTS
TABLE 29. ERYTECH PHARMA: PRODUCT PORTFOLIO
TABLE 30. LEADIANT BIOSCIENCES, INC. (SIGMA-TAU PHARMACEUTICALS INC.): COMPANY SNAPSHOT
TABLE 31. LEADIANT BIOSCIENCES, INC. (SIGMA-TAU PHARMACEUTICALS INC.): OPERATING SEGMENTS
TABLE 32. LEADIANT BIOSCIENCES, INC. (SIGMA-TAU PHARMACEUTICALS INC.): PRODUCT PORTFOLIO
TABLE 33. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 34. NOVARTIS AG: OPERATING SEGMENTS
TABLE 35. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 36. PFIZER, INC: COMPANY SNAPSHOT
TABLE 37. PFIZER, INC: OPERATING SEGMENTS
TABLE 38. PFIZER, INC: PRODUCT PORTFOLIO
TABLE 39. RARE DISEASE THERAPEUTICS, INC.: COMPANY SNAPSHOT
TABLE 40. RARE DISEASE THERAPEUTICS, INC.: OPERATING SEGMENT
TABLE 41. RARE DISEASE THERAPEUTICS, INC.: PRODUCT PORTFOLIO
TABLE 42. SANOFI: COMPANY SNAPSHOT
TABLE 43. SANOFI: OPERATING SEGMENTS
TABLE 44. SANOFI: PRODUCT PORTFOLIO
TABLE 45. SPECTRUM PHARMACEUTICALS, INC: COMPANY SNAPSHOT
TABLE 46. SPECTRUM PHARMACEUTICALS, INC.: OPERATING SEGMENT
TABLE 47. SPECTRUM PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
TABLE 48. TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT
TABLE 49. TAKEDA PHARMACEUTICAL COMPANY LIMITED: OPERATING SEGMENTS
TABLE 50. TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01. ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA THERAPEUTICS MARKET SEGMENTATION
FIGURE 02. TOP WINNING STRATEGIES, BY YEAR, 2017-2019*
FIGURE 03. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2017-2019* (%)
FIGURE 04. TOP WINNING STRATEGIES, BY COMPANY, 2017-2019*
FIGURE 05. BARGAINING POWER OF SUPPLIERS
FIGURE 06. THREAT OF NEW ENTRANTS
FIGURE 07. THREAT OF SUBSTITUTES
FIGURE 08. COMPETITIVE RIVALRY
FIGURE 09. BARGAINING POWER AMONG BUYERS
FIGURE 10. TOP IMPACTING FACTORS
FIGURE 11. AMGEN INC.: NET SALES, 2016–2018 ($MILLION)
FIGURE 12. AMGEN INC.: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 13. AMGEN INC.: REVENUE SHARE BY REGION, 2018(%)
FIGURE 14. BRISTOL-MYERS SQUIBB COMPANY: NET SALES, 2016–2018 ($MILLION)
FIGURE 15. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 16. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE BY REGION, 2018(%)
FIGURE 17. NOVARTIS AG: NET SALES, 2016–2018 ($MILLION)
FIGURE 18. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 19. NOVARTIS AG: REVENUE SHARE BY REGION, 2018(%)
FIGURE 20. PFIZER, INC: NET SALES, 2016–2018 ($MILLION
FIGURE 21. PFIZER, INC: REVENUE SHARE BY SEGMENT/TECHNOLOGY, 2018 (%)
FIGURE 22. PFIZER, INC: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 23. SANOFI: NET SALES, 2016–2018 ($MILLION)
FIGURE 24. SANOFI: REVENUE SHARE BY SEGMENT, 2018 (%
FIGURE 25. SANOFI: REVENUE SHARE BY REGION, 2018(%)
FIGURE 26. SPECTRUM PHARMACEUTICALS, INC: NET SALES, 2016–2018 ($MILLION)
FIGURE 27. SPECTRUM PHARMACEUTICALS, INC.: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 28. SPECTRUM PHARMACEUTICALS, INC.: REVENUE SHARE BY REGION, 2018(%)
FIGURE 29. TAKEDA PHARMACEUTICAL COMPANY LIMITED: NET SALES, 2016–2018 ($MILLION)
FIGURE 30. TAKEDA PHARMACEUTICAL COMPANY LIMITED: REVENUE SHARE BY REGION, 2018(%)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook